Abstract
Executive Summary
This report examines the emerging, fast-growing worldwide market for
next-generation genome sequencing systems and services. The makers of the new
sequencing systems are competing in the race to drive down the cost of
sequencing a human genome to $1,000 or less. At that cost, life scientists
will be able sequence human genomes at the massive scale needed to better
understand human variation and help open the gateway to personalized medicine.
The first wave of the commercial high-throughput genome sequencers has seen a
rapid uptake from life science research customers at genome centers and
research service providers from North America, Europe and Asia. This study
looks at the basic technologies that these new DNA sequencers use and what
kinds of applications and research projects that the scientists are doing.
The new platforms can help accelerate the research capabilities of basic
academic medical research, pharmaceutical and biotech drug discovery and
diagnostic developments. The report also studies the research service
providers that outsource to pharma and biotech companies because the
technologies might help them become more productive faster.
This report is for business executives, entrepreneurs, venture capitalists,
investors, product managers, research managers, business development managers,
and other decision makers. The next-generation genome sequencing products and
services discussed include technologies from Illumina, Roche/ 454, Applied
Biosystems, Danaher Motion, Helicos Biosciences, Pacific Biosciences and
others.
This study discusses its interesting topics with key findings. The new data
presented estimates that the total next-generation genome sequencing market
size will reach $484 million in 2008 and grow at a high rate. It reviews the
activities of 18 companies. The report uses 38+ figures and tables to
illustrate the findings. The study features convenient tables that help the
reader scan the details of key trends, market segmentation, forecasts, M&As,
alliances, grant funding, patents and the like.
| 
View Cart
